Cipla Imatinib Adult

Cipla Imatinib Adult - Precautions | Dosage

This article was medically reviewed by M.Pharm, Marko Tanaskovic on Tue, 14 Jan 2020. To read more about an author, click here.

Cipla Imatinib Adult is a medicine containing active substance called imatinib and belongs to antineoplastic drugs that inhibit bcr-abl tyrosine kinase, which is present in patients with chronic myeloid leukemia who have Philadelphia chromosome. It works by inhibiting proliferation (anti-proliferative action) and inducing apoptosis or cell death of tumor cells.

Cipla Imatinib Adult is metabolized via an enzyme called CYP3A4, and this enzyme is responsible for the metabolism of more than 50% of drugs. Therefore, Cipla Imatinib Adult can interact with many drugs.

This drug is indicated in the treatment of chronic myeloid leukemia, acute lymphoblastic leukemia, hypereosinophilic syndrome, chronic eosinophilic leukemia, and other myeloproliferative diseases, in patients who have Philadelphia chromosome (Philadelphia-positive patients).

It is also used in the treatment of aggressive systemic mastocytosis, gastrointestinal stromal tumors and dermatofibrosarcoma.


Congestive heart failure and left ventricular dysfunction have been reported in patients taking this drug, although most patients in whom this adverse reaction was reported had other diseases (comorbidities), so the causal relationship between the drug and this side effect cannot be established with certainty. However, cardiac function should be regularly monitored in patients taking this medication, and if any cardiac problems occur, they should be treated promptly.

Cipla Imatinib Adult has hepatotoxic properties and liver enzymes (AST, ALT, alkaline phosphatase, and others) should be monitored before and during the treatment (at least once a month). If a substantial increase in these liver enzymes occurs, a dose reduction should be considered. Patients are advised to contact their physician if there are any signs of liver damage (abdominal pain, jaundice, nausea, loss of appetite, etc.).

Cipla Imatinib Adult can cause irritation of the gastrointestinal tract, and it is recommended to take this drug with food and large glass of water (at least 250 ml). In rare cases, this medicine can cause fatal gastrointestinal perforations. If you are experiencing stomach problems (such as, black stools or the presence of blood in the stool), contact your doctor immediately.

Cipla Imatinib Adult can cause Stevens-Johnson syndrome and epidermal toxic necrolysis, which are serious skin lesions that can lead to sepsis, pneumonia and organ failure, with a fatal outcome. Contact your doctor immediately should you notice any skin changes or flu-like symptoms.

Serious fluid retention and edema have been reported in a relatively large number of patients (more than 10%). This adverse reaction was more frequent in patients older than 65 years of age. Patients should therefore be regularly weighed, and if there is a substantial weight gain or swelling, you should inform your doctor immediately.

Cipla Imatinib Adult Use During Pregnancy and Breastfeeding

The FDA classifies this drug in category D, which means that Cipla Imatinib Adult has toxic effects on the fetus, and women who may become pregnant are advised to use appropriate contraceptive methods and avoid pregnancy while using this drug.

It is unknown whether Cipla Imatinib Adult is excreted in breast milk, but because of the potential toxic effects of this drug, breastfeeding should be avoided while using this medicine.


Your doctor will determine the appropriate dose of medicine to take. The dose of medication to be taken depends largely on the type of carcinoma you have, the condition you are in, as well as your weight / body surface area and age.

Only an experienced doctor can determine the right dose for you.

Cipla Imatinib Adult is available in different dosage forms. Doses up to 600 mg can be taken once a day, and if the dose is greater than 600 mg (e.g. 800 mg) then the dose should be divided into multiple daily doses.

Take your medicine with plenty of fluids along with a meal to reduce the risk of gastrointestinal irritation.


More than 500 drug interactions of Cipla Imatinib Adult and other medicines have been described, of which 75 were classified as major.

Cipla Imatinib Adult should not be used with the following medicines:

  • Adalimumab and baricitinib - medicines used in the treatment of arthritis. Concomitant use can lead to serious life-threatening infections.
  • Acalabrutinib - a drug used to treat Non-Hodgkin lymphoma. Concomitant administration increases the risk of gastrointestinal problems (nausea, vomiting, diarrhea, abdominal pain, etc.), arrhythmias, decreased blood cell counts, and cancers.
  • Alfentanil - an opioid analgesic used in the treatment of severe pain. Concomitant administration increases the risk of respiratory depression, arrhythmia, and low blood pressure.
  • Avanafil - a medicine used to treat impotence. Concomitant administration leads to a significant increase in the concentration of avanafil in the blood, which can lead to loss of vision or hearing, arrhythmias, chest pain, and low blood pressure.
  • Avatrombopag - a medicine used to treat thrombocytopenia. Concomitant administration can lead to serious complications, such as thrombophlebitis and portal vein thrombosis.
  • Cisasprid - a gastrointestinal prokinetic drug. Concomitant administration increases the risk of severe cardiac arrhythmias.
  • Bosutinib - a drug used to treat cancer. Concomitant use can lead to serious side effects, such as bleeding, infections, and hepatotoxicity.
  • Clozapine - a drug used in the treatment of schizophrenia. Clozapine can reduce the number of blood cells, just like Cipla Imatinib Adult, and concomitant use should be avoided.
  • Colchicine - a drug used in the treatment of gout. Concomitant administration may lead to neurotoxic, nephrotoxic, hepatotoxic effects and muscle damage.

Tell your doctor about any medicines you are taking.

Side Effects

Cipla Imatinib Adult can cause the following side effects:

  • Diarrhea.
  • Abdominal pain.
  • Nausea.
  • Vomiting.
  • Muscle pain.
  • Bone pain.
  • Joint pain.
  • Rash.
  • Edema.
  • Fluid retention.
  • Headache.
  • Upper respiratory tract infections.
  • Weight gain.
  • Insomnia.
  • Depression.
  • Bleeding.
  • Nasopharyngitis.
  • Anxiety.
  • Heart failure.
  • Hepatotoxicity.
  • Allergic reaction.

Inform your doctor at once should you notice any side effects.


  1. FDA
  2. EMA

Information on this website are provided for educational purposes only and are not intended for medical advice, diagnosis or treatment.

If you have any concerns or questions about your health, you should always consult with a physician or other health-care professional.